Literature DB >> 20689420

Thyroid hormones and cancer: clinical studies of hypothyroidism in oncology.

Aleck H Hercbergs1, Osnat Ashur-Fabian, David Garfield.   

Abstract

PURPOSE OF REVIEW: To collect and assess clinical reports of a putative relationship between thyroid state and the biology of cancers of various types. RECENT
FINDINGS: A number of prospective case-control studies reviewed here have suggested that subclinical hyperthyroidism increases risk of certain solid tumors and that spontaneous hypothyroidism may delay onset or reduce aggressiveness of cancers. Small case studies have reached similar conclusions. A controlled prospective trial of induced hypothyroidism beneficially affected the course of glioblastoma. A context in which to interpret such findings is the recent description of a plasma membrane receptor for thyroid hormone on cancer cells and dividing tumor-associated endothelial cells.
SUMMARY: Accumulating clinical evidence may justify new, broadly-based controlled studies in cancer patients of the possible contribution of thyroid hormone to tumor behavior.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20689420     DOI: 10.1097/MED.0b013e32833d9710

Source DB:  PubMed          Journal:  Curr Opin Endocrinol Diabetes Obes        ISSN: 1752-296X            Impact factor:   3.243


  33 in total

Review 1.  Iodothyronine deiodinases and cancer.

Authors:  A Piekiełko-Witkowska; A Nauman
Journal:  J Endocrinol Invest       Date:  2011-05-27       Impact factor: 4.256

2.  Thyroid dysfunction in patients treated with sunitinib or sorafenib.

Authors:  Julia Clemons; Dexiang Gao; Mary Naam; Kathryn Breaker; David Garfield; Thomas W Flaig
Journal:  Clin Genitourin Cancer       Date:  2012-09-25       Impact factor: 2.872

3.  The thyroid hormone-αvβ3 integrin axis in ovarian cancer: regulation of gene transcription and MAPK-dependent proliferation.

Authors:  E Shinderman-Maman; K Cohen; C Weingarten; D Nabriski; O Twito; L Baraf; A Hercbergs; P J Davis; H Werner; M Ellis; O Ashur-Fabian
Journal:  Oncogene       Date:  2015-07-13       Impact factor: 9.867

4.  Thyroid Hormone Controls Breast Cancer Cell Movement via Integrin αV/β3/SRC/FAK/PI3-Kinases.

Authors:  Marina Inés Flamini; Ivonne Denise Uzair; Gisela Erika Pennacchio; Flavia Judith Neira; Joselina Magali Mondaca; Fernando Dario Cuello-Carrión; Graciela Alma Jahn; Tommaso Simoncini; Angel Matías Sanchez
Journal:  Horm Cancer       Date:  2017-01-03       Impact factor: 3.869

5.  Medically induced euthyroid hypothyroxinemia may extend survival in compassionate need cancer patients: an observational study.

Authors:  Aleck Hercbergs; Rebecca E Johnson; Osnat Ashur-Fabian; David H Garfield; Paul J Davis
Journal:  Oncologist       Date:  2014-11-19

Review 6.  Does thyroid dysfunction increase the risk of breast cancer? A systematic review and meta-analysis.

Authors:  Y Fang; L Yao; J Sun; R Yang; Y Chen; J Tian; K Yang; L Tian
Journal:  J Endocrinol Invest       Date:  2017-05-17       Impact factor: 4.256

7.  Tetraiodothyroacetic acid-conjugated PLGA nanoparticles: a nanomedicine approach to treat drug-resistant breast cancer.

Authors:  Dhruba J Bharali; Murat Yalcin; Paul J Davis; Shaker A Mousa
Journal:  Nanomedicine (Lond)       Date:  2013-02-28       Impact factor: 5.307

8.  Clinical impact of microscopic extrathyroidal extension in patients with papillary thyroid microcarcinoma treated with hemithyroidectomy.

Authors:  D Ahn; J H Sohn; J H Jeon; J Y Jeong
Journal:  J Endocrinol Invest       Date:  2014-01-09       Impact factor: 4.256

9.  The thyroid status reprograms T cell lymphoma growth and modulates immune cell frequencies.

Authors:  H A Sterle; M L Barreiro Arcos; E Valli; M A Paulazo; S P Méndez Huergo; A G Blidner; F Cayrol; M C Díaz Flaqué; A J Klecha; V A Medina; L Colombo; G A Rabinovich; G A Cremaschi
Journal:  J Mol Med (Berl)       Date:  2015-11-13       Impact factor: 4.599

10.  Elevated Free Thyroxine Levels Are Associated with Poorer Overall Survival in Patients with Gastroesophageal Cancer: A Retrospective Single Center Analysis.

Authors:  H C Puhr; P Wolf; A S Berghoff; S F Schoppmann; M Preusser; Aysegul Ilhan-Mutlu
Journal:  Horm Cancer       Date:  2019-12-28       Impact factor: 3.869

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.